共 187 条
- [1] Tan H(2023)Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation Biomed Pharmacother. 164 114916-254
- [2] Gong Y(2007)Epstein-Barr virus-related lymphoproliferative disorders Curr Hematol Malig Rep. 2 249-658
- [3] Liu Y(2019)Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors J Clin Pathol. 72 651-821
- [4] Long J(2015)The immunology of Epstein-Barr virus-induced disease Annu Rev Immunol. 33 787-1283
- [5] Luo Q(2017)Epstein-Barr virus lymphoproliferative disease after solid organ transplantation Cytotherapy 19 1270-177
- [6] Faleti OD(2011)A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas J Virol. 85 165-27
- [7] Lyu X(2009)The biology of Hodgkin’s lymphoma Nat Rev Cancer. 9 15-573
- [8] Wagner-Johnston ND(2021)Molecular basis of Epstein–Barr virus latency establishment and lytic reactivation Viruses 13 2344-529
- [9] Ambinder RF(2017)Epstein-Barr virus (EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+ DLBCL Immunology 152 562-E64
- [10] Kerr JR(2017)Epstein-Barr virus-positive follicular lymphoma Mod Pathol. 30 519-282